文献速递神经肿瘤

整体治疗时间与放疗中断对胶质母细胞瘤预后的影响及不同生物学亚组的差异

Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groups.
PubMed 文献 · J Neurooncol · 2025-09-25

该回顾性单中心队列研究纳入166例IDH野生型胶质母细胞瘤成人患者,分析整体治疗时间(OTT)和放疗中断与生存的关系。结果显示OTT>48天是独立不良预后因素(HR=1.41,p=0.009),中位OS为10个月 vs 20个月(p=0.003),且该负面影响在MGMT启动子甲基化亚组中更显著(交互p=0.018)。

要点

  • OTT>48天与更差生存独立相关,中位OS 10个月 vs 20个月。
  • 多次放疗中断进一步降低OS,临床性中断比单次技术性中断预后更差。
  • MGMT甲基化患者对治疗时间延长更敏感,交互p=0.018。

核心结论

  • 延长的OTT和放疗中断是IDH野生型胶质母细胞瘤患者生存不良的独立相关因素。
  • 在MGMT启动子甲基化等生物学有利亚组中,OTT延长的负面影响更为显著。

研究设计与样本

  • 回顾性单中心队列研究,纳入2016年1月至2024年1月间166例组织学确诊的IDH野生型胶质母细胞瘤成人患者。
  • 所有患者接受标准同步放化疗及辅助替莫唑胺治疗。
  • OTT定义为放疗开始至结束的总天数(含所有中断),以48天为截断值进行分组。
  • 主要终点为OS和PFS,采用Kaplan-Meier法和Cox回归模型分析。

主要发现

  • 中位OTT为43天(范围40-65天)。
  • OTT≤48天组中位OS显著长于OTT>48天组(20个月 vs 10个月,p=0.003)。
  • 多因素Cox回归确认OTT>48天为独立负性预后因素(HR=1.41,p=0.009)。
  • 多次中断(无论原因)进一步降低OS,尤其在MGMT甲基化且EGFR低表达患者中。
  • OTT延长的负性影响在MGMT甲基化亚组中显著更明显(交互作用p=0.018)。

关键数值与推荐

  • OTT截断值采用48天(基于既往证据)。
  • OTT>48天为独立负性预后因素:HR=1.41,p=0.009。
  • OTT≤48天 vs >48天中位OS:20个月 vs 10个月,p=0.003。
  • MGMT甲基化亚组中OTT延长影响的交互作用p=0.018。

临床怎么用

  • 应严格遵循放化疗时间安排,尽量减少可避免的放疗中断和延迟。
  • 对MGMT启动子甲基化等生物学有利患者,尤需关注治疗时间延长带来的风险。
  • 分子分型可能有助于识别对治疗延迟最敏感的患者,支持个体化时间敏感管理。

局限性

  • 回顾性单中心研究设计。
  • 样本量有限(166例)。
  • 结果需进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, with a median overall survival (OS) rarely exceeding 15 months despite multimodal therapy. While established prognostic factors include age, Karnofsky Performance Status (KPS), and molecular features such as MGMT promoter methylation and IDH mutation status, increasing attention has focused on the role of treatment timing as a potentially modifiable prognostic determinant. In particular, Overall Treatment Time (OTT)-the number of calendar days from the first to the last radiotherapy fraction-may impact survival by enabling tumor repopulation when extended or interrupted. METHODS: We conducted a retrospective monocentric cohort study of 166 consecutive adult patients with histologically confirmed IDH-wild-type glioblastoma treated with standard concurrent chemoradiotherapy and adjuvant temozolomide between January 2016 and January 2024. OTT was defined as the total number of days from radiotherapy start to end, including all interruptions. A cutoff of 48 days was adopted based on prior evidence. Patients were stratified according to OTT, number and cause of radiotherapy interruptions, and molecular status (MGMT promoter methylation and EGFR amplification). The primary endpoints were OS and progression-free survival (PFS), analyzed with Kaplan-Meier and Cox regression models. RESULTS: Median OTT was 43 days (range: 40-65). Patients with OTT ≤ 48 days had a significantly longer median OS than those with OTT > 48 days (20 vs. 10 months, p = 0.003). Multivariable Cox regression confirmed OTT > 48 days as an independent negative prognostic factor (HR = 1.41, p = 0.009). Multiple interruptions, regardless of cause, further reduced OS, particularly in patients with MGMT-methylated tumors and low EGFR expression. Clinical interruptions-often due to toxicity-were associated with significantly worse outcomes than single technical interruptions. Notably, the negative impact of prolonged OTT was significantly more pronounced in the MGMT-methylated subgroup (p for interaction = 0.018), suggesting a biologically distinct vulnerability to treatment delays. CONCLUSIONS: This study demonstrates that prolonged OTT and radiotherapy interruptions are independently associated with inferior survival in patients with IDH-wild-type glioblastoma, particularly in biologically favorable subgroups such as MGMT-methylated tumors. These findings underscore the importance of strict adherence to treatment schedules and minimizing avoidable delays. Molecular profiling may aid in identifying patients most vulnerable to the adverse effects of treatment prolongation, supporting a more personalized and time-sensitive approach to GBM management. Further prospective validation is warranted.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tini P, Donnini F, Marampon F, et al. Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groups. J Neurooncol. 2025. PMID: 40996682. doi:10.1007/s11060-025-05215-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。